Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

BACKGROUND: The trastuzumab, pertuzumab, and docetaxel (TPD) regimen is strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER) 2-positive breast cancer. Monitoring the host microenvironments in cancer plays a significant role in pr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Transl Med
Egile Nagusiak: Takada, Koji, Kashiwagi, Shinichiro, Goto, Wataru, Asano, Yuka, Takahashi, Katsuyuki, Takashima, Tsutomu, Tomita, Shuhei, Ohsawa, Masahiko, Hirakawa, Kosei, Ohira, Masaichi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2018
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5883877/
https://ncbi.nlm.nih.gov/pubmed/29615076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1460-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak